Prof. PeptideProf. Peptide

GHRP-2

Growth HormoneResearch-Grade

Last reviewed: September 20, 2026 · Updated

Quick Facts

What it is
A lab-made peptide that signals the pituitary to release the body's own growth hormone — a potent GH secretagogue that also stimulates appetite through the ghrelin receptor.
How it's taken
Subcutaneous injection in research; a single IV dose for the Japanese diagnostic (pralmorelin); oral administration also studied
Half-life
~30 minutes (plasma)
Typical research dose
100–300 mcg, one to three times daily on an empty stomach, in 8–12 week cycles
Research status
Not FDA-approved — but approved in Japan as pralmorelin, a GH-stimulation diagnostic. Research use only elsewhere; WADA-prohibited (S2).
On this page
  1. 1.Where to source GHRP-2
  2. 2.What is GHRP-2?
  3. 3.How does GHRP-2 work?
  4. 4.What is GHRP-2 used for?
  5. 5.How long does GHRP-2 take to work?
  6. 6.How is GHRP-2 dosed?
  7. 7.How is GHRP-2 administered?
  8. 8.What does GHRP-2 stack well with?
  9. 9.What are the side effects of GHRP-2?
  10. 10.Does GHRP-2 interact with other drugs?
  11. 11.How should GHRP-2 be stored?
  12. 12.What are the limitations of GHRP-2 research?
  13. 13.GHRP-2 FAQ
  14. 14.References
  15. 15.Published Studies
  16. 16.Prices and lab checks

Where to source GHRP-2

GHRP-2 is sold only as a research-grade peptide outside its diagnostic approval. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Vital Core Research20% off

Vanguard Laboratory · per-lot certificates on each product listing

Shop Vital Core Research
Oasis Labs15% off

Bioviridian-tested · verifiable COAs

Shop Oasis Labs
Fusion Peptide15% off
Shop Fusion Peptide
Peptides.gg15% off

Per-batch COAs

Shop Peptides.gg
Compare prices across 20 vendors

See all 117 verified vendors

What is GHRP-2?

GHRP-2 (pralmorelin, also carried under the developmental codes KP-102 and GHRP-KP; D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR-1a). It is more potent at releasing GH than the original GHRP-6 and more GH-selective, though not fully cortisol-sparing like Ipamorelin. Its GH-releasing action is reliable enough that it is used as an approved diagnostic test for GH deficiency in Japan. Most research combines it with a GHRH analog such as CJC-1295 for a larger, dual-pathway GH pulse. New to peptide research? Start with the basics

Reported benefits:

  • Potent, reliable pulsatile GH release via the ghrelin receptor
  • Raises IGF-1 downstream of GH; supports lean mass and fat loss (extrapolated)
  • Appetite stimulation (ghrelin-like) — useful in cachexia research
  • Validated GH-provocative diagnostic (approved as pralmorelin in Japan)
  • Synergizes with GHRH analogs (CJC-1295/sermorelin) for a bigger GH pulse
  • Caveat: not cortisol-sparing — modest cortisol/prolactin rise

Common research dose: No human trial has established a bolus-injection research dose; reported research-community practice is 100–300 mcg subcutaneously, 1–3 times daily, on an empty stomach — bedtime is the most common single-dose timing. A randomized human trial found the GH and appetite response is dose-dependent between 0.1 and 1 mcg/kg/hour by continuous infusion, and community sources report that doses much above ~1 mcg/kg add cortisol, not GH.

Where to buy: Prof. Peptide maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does GHRP-2 work?

GHRP-2 is a synthetic hexapeptide that activates the ghrelin/growth-hormone-secretagogue receptor (GHSR-1a) on pituitary somatotrophs and hypothalamic neurons — the same receptor the natural hormone ghrelin uses. Receptor activation drives a Gq/PLC calcium cascade that triggers a pulse of growth-hormone release, while also amplifying GHRH signaling and blunting somatostatin. Unlike ipamorelin, GHRP-2 is not fully GH-selective — it produces a modest rise in cortisol, prolactin, and ACTH.

  1. GHSR-1a receptor activation [1][2]. GHRP-2 binds the ghrelin receptor (GHSR-1a) on somatotrophs and in the hypothalamus. This is the receptor for which ghrelin is the endogenous ligand [2]; GHRP-2 is a synthetic ghrelin mimic optimized for GH release.
  2. Calcium/PLC signaling [1]. Receptor activation couples to Gq/11, driving phospholipase-C and IP3-mediated intracellular calcium rise in somatotrophs — a mechanism distinct from the Gs/cAMP pathway used by GHRH-class peptides, which is why GHRP-2 and CJC-1295 act synergistically.
  3. Pulsatile GH release + somatostatin suppression [4]. GHRP-2 amplifies the natural pulsatile GH pattern rather than producing a continuous flood, and it reduces the inhibitory tone of somatostatin — preserving the feedback loops that make secretagogues safer than direct GH.
  4. Appetite via the ghrelin pathway [3]. Because GHRP-2 activates the ghrelin receptor, it also stimulates appetite — human infusion increased food intake ~36% versus saline [3]. This is a smaller effect than GHRP-6 but a defining feature of the ghrelin-receptor agonists.
  5. Partial selectivity [4]. GHRP-2 raises cortisol, prolactin, and ACTH modestly alongside GH — more than ipamorelin, less than GHRP-6. This is the trade-off for its strong GH-releasing potency.

What is GHRP-2 used for?

GHRP-2's evidence base is the strongest of the classic GHRPs on the GH axis: it is a validated GH-stimulation diagnostic (approved as pralmorelin in Japan), with human data on GH/IGF-1 elevation and appetite. Body-composition and anti-aging uses are extrapolated from GH physiology and clinical practice rather than controlled trials. It is not FDA-approved.

  1. Growth-hormone stimulation / diagnostics [4]. GHRP-2 reliably provokes a GH pulse; a single 100 mcg IV dose is used as a provocative test for GH deficiency, and it is approved for this diagnostic use in Japan (pralmorelin).
  2. IGF-1 elevation [4]. Repeated GHRP-2 dosing raises IGF-1 downstream of GH — the mechanism behind its research use for body composition and recovery.
  3. Appetite and body weight [3][5]. Human and pediatric studies document increased food intake and body weight with GHRP-2, reflecting its ghrelin-receptor activity — relevant to research on cachexia and appetite loss.
  4. Body composition (extrapolated). Lean-mass and fat-loss effects are inferred from GH/IGF-1 physiology and clinical observation, not from controlled GHRP-2 trials.
  5. Limited long-term human data [6]. As the class review notes, controlled long-term safety and efficacy trials of GHRP-2 are lacking; most non-diagnostic use is off-label or research-grade.

How long does GHRP-2 take to work?

GHRP-2 produces an immediate GH pulse but cumulative physical effects that build over weeks. The GH peak occurs within roughly 15–60 minutes of a dose; downstream IGF-1 elevation appears within days of consistent dosing, and body-composition changes over 8–12 weeks.

The GH response is fast — a measurable pulse within about 15–60 minutes of a subcutaneous dose, which is why GHRP-2 works as a provocative diagnostic. IGF-1 rises within days of consistent dosing. Subjective and body-composition changes (recovery, lean mass, fat loss) build over 8–12 weeks. Because the plasma half-life is commonly reported as short (roughly 30 minutes, though no published pharmacokinetic study or label has been identified establishing this figure for GHRP-2), each dose is a discrete pulse — timing (bedtime, empty stomach) matters more than sustained blood levels. Expect a transient appetite increase after dosing.

How is GHRP-2 dosed?

No human trial has established a repeated-use, bolus-injection research dose for GHRP-2. The figures below are split into what the cited literature administered and, separately, community-reported practice.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

Human RCT (dose-response, food intake). Laferrère et al. (Obesity, 2006, PMID 16861611) ran a double-blind, randomized, placebo-controlled trial in 19 healthy adults (10 lean, 9 obese), giving a subcutaneous infusion of GHRP-2 at a high dose (1 mcg/kg/hour) or low dose (0.1 mcg/kg/hour) for 270 minutes (4.5 hours) — a continuous infusion, not a bolus injection. Food intake rose 10.2% at the low dose and 33.5% at the high dose versus placebo, and serum GH rose dose-dependently in all subjects; obesity status did not change the response. For a roughly 80 kg adult, the high-dose arm delivered on the order of 360 mcg total over the 4.5-hour infusion — broadly the same order of magnitude as the bolus doses reported below, but administered continuously rather than as a single subcutaneous shot.

Human observational (diagnostic dose, not a repeated research protocol). Chihara et al. (Eur J Endocrinol, 2007, PMID 17609397) is a diagnostic-accuracy study, not a randomized trial: 77 healthy subjects and 58 GH-deficient patients each received a single 100 mcg intravenous dose of GHRP-2 after an overnight fast, and peak GH at 60 minutes was used to distinguish the groups. This establishes a validated single diagnostic IV dose (approved in Japan as pralmorelin) — it says nothing about a repeated subcutaneous research protocol, and the international approval as a diagnostic should not be read as evidence for any ongoing-use dose.

Community-reported practice (unverified)

Reported research-community practice — attributed to where it circulates, not to either study above, and not independently verified by Prof. Peptide — is 100–300 mcg subcutaneously per bolus injection, once to three times daily, on an empty stomach, most often at bedtime, for 8–12 week cycles. This diverges from the cited RCT in route and administration pattern (a discrete subcutaneous bolus versus the trial’s 4.5-hour continuous infusion) and from the diagnostic study in intent and route (repeated subcutaneous dosing for a GH/appetite effect versus a single intravenous diagnostic challenge). No source was found deriving the community bolus figure from either study’s own numbers.

GHRP-2 is most often stacked with CJC-1295 (ghrelin receptor + GHRH receptor = synergistic GH release). The pre-blended GH Stack uses the same principle with ipamorelin.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

How is GHRP-2 administered?

GHRP-2 is given as a subcutaneous injection using a small insulin syringe, on an empty stomach — food-driven insulin blunts the GH response. Bedtime dosing aligns with the natural overnight GH peak. For syringe mechanics and units-vs-mcg conversion, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection. Common sites: abdomen, thigh, upper arm.
  2. Time of day. Bedtime is most common; a pre-workout dose is sometimes added, with an empty stomach reported in all cases.
  3. With or without food. An empty stomach is reported required (2+ hours after eating, no food for ~30 min after) — insulin blunts GH release.
  4. Site rotation. Reported practice rotates sites each injection, staying at least 1 inch from the previous site.
  5. Appetite spike. Increased hunger is reported for 30–60 minutes after dosing (ghrelin-receptor activation).
  6. Missed dose. Reported practice skips and resumes the next scheduled dose, without doubling up.
  7. Cycle structure. 8–12 weeks on, with time off.

Timing context. GHRP-2's short (~30-minute) half-life means each dose is a discrete GH pulse. Stacking the dose onto the natural overnight GH surge (bedtime) and keeping the stomach empty are the two variables that most affect the response. Dose size has a ceiling — beyond roughly 1 mcg/kg, additional GHRP-2 mostly adds cortisol and prolactin, not GH.

AspectReported
FrequencyContinuous ghrelin-receptor-agonist exposure is documented to desensitize the receptor (Camiña et al., 2004, Endocrinology) — the real mechanism cited as the reason to cycle. The specific interval reported here is community practice, not itself trial-derived: 1–3× daily, most users dosing once at bedtime, cycled rather than continuous
Best time of dayThe most reproducible endogenous GH pulse occurs shortly after sleep onset, coinciding with slow-wave sleep — established sleep endocrinology (Van Cauter & Plat, 1996, J Clin Endocrinol Metab); bedtime dosing on that reasoning is a commonly reported research convention, not itself trial-tested.
FoodEmpty stomach required — 2+ hours after eating, 30+ min before next meal
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to GHRP-2.
Half-life~30 minutes (plasma)
Steady-statePer-pulse effect — each dose triggers a discrete GH pulse rather than a sustained level

Reconstitution math. GHRP-2 research vials are typically 5 mg. Because doses are small (100–300 mcg), 2 mL or 3 mL reconstitution gives more precise unit draws. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.

BAC waterConcentration100 mcg dose200 mcg dose300 mcg dose500 mcg dose
1 mL5 mg/mL2 units4 units6 units10 units
2 mL2.5 mg/mL4 units8 units12 units20 units
3 mL1.67 mg/mL6 units12 units18 units30 units

Units vs mcg. At a 5 mg vial, each unit delivers 50 mcg at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL. For a primer on reading insulin syringes, see our guide on syringes and injection technique.

What does GHRP-2 stack well with?

GHRP-2's canonical pairing is a GHRH analog (CJC-1295 or sermorelin) — different receptor, synergistic GH pulse. It does NOT stack usefully with other ghrelin-receptor agonists (GHRP-6, hexarelin, ipamorelin, MK-677) — those are redundant. Recovery peptides pair cleanly.

  1. CJC-1295 / sermorelin (GHRH analogs). CJC-1295 or Sermorelin activate the GHRH receptor while GHRP-2 activates the ghrelin receptor — dual-pathway synergy. The GH Stack uses this principle.
  2. Recovery peptides. BPC-157 and TB-500 pair cleanly for tissue repair during a GH-driven anabolic block.
  3. Conflicts: other ghrelin-receptor agonists. GHRP-6, Hexarelin, Ipamorelin, and MK-677 hit the same receptor — combining them is redundant.
  4. Resistance training. Exercise-induced GH release adds to the GHRP-2 pulse.

What are the side effects of GHRP-2?

GHRP-2 is not cortisol-sparing. The most common effects are a transient appetite spike, mild injection-site reactions, and GH-related water retention or tingling. Its distinguishing caveat versus ipamorelin is a modest rise in cortisol and prolactin. Long-term controlled human safety data is limited.

Common (most users)

  1. Increased appetite. Transient (30–60 minutes) via ghrelin-receptor activation.
  2. Injection-site reactions. Mild redness or irritation, usually brief.
  3. Mild water retention / tingling. GH-related; often eases with lower doses.

Less common (moderate)

  1. Modest cortisol / prolactin rise. Smaller than GHRP-6 but present; can cause lethargy or, rarely, mild prolactin-related effects at higher doses.
  2. Mild headache or flushing. Inconsistent across users.
  3. Reduced insulin sensitivity. Sustained GH elevation can modestly raise fasting glucose.

Serious (rare)

  1. Long-term human safety data is limited. Most controlled studies are short or diagnostic single-dose.
  2. Theoretical tumor-growth risk. GH/IGF-1 elevation could accelerate a pre-existing malignancy, so active cancer is treated as a theoretical exclusion in research contexts.

GHRP-2 trades a little selectivity for stronger GH release than ipamorelin. Users who are sensitive to cortisol or prolactin effects, or who want the cleanest long-term profile, often prefer ipamorelin; those prioritizing GH potency choose GHRP-2. Monitor IGF-1 and glucose with sustained use.

Does GHRP-2 interact with other drugs?

GHRP-2's interactions are mostly about redundancy with other ghrelin-receptor agonists and blunting by insulin/steroids. No major pharmacokinetic drug-drug interactions are reported.

  1. Insulin and corticosteroids. Both blunt GH release; time dosing away from meals and steroid administration.
  2. Other ghrelin-receptor agonists (GHRP-6, hexarelin, ipamorelin, MK-677). Redundant via the same receptor; no additive GH benefit.
  3. Direct human growth hormone (HGH). Combining is generally unnecessary — GHRP-2 stimulates endogenous GH, and exogenous HGH bypasses the feedback that makes secretagogues safer.
  4. No significant drug-drug pharmacokinetic interactions reported in published research.

How should GHRP-2 be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade GHRP-2 remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is never frozen.
  5. GHRP-2 is stored protected from light, in the original carton.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of GHRP-2 research?

GHRP-2 is well characterized on the GH axis but not FDA-approved for therapy; its only regulatory approval is as a diagnostic agent (pralmorelin) in Japan. Body-composition and anti-aging claims rest on GH physiology and clinical practice, not controlled GHRP-2 trials. It is WADA-prohibited in sport.

GHRP-2 is not FDA-approved for any therapeutic use. Its GH-releasing potency is well documented — enough to support an approved diagnostic role in Japan — but that does not translate to approved treatment indications elsewhere.

Evidence for body-composition, recovery, and anti-aging use is extrapolated from GH/IGF-1 physiology and clinical observation rather than controlled long-term trials of GHRP-2 itself. It is not cortisol-sparing, a real difference from ipamorelin.

The World Anti-Doping Agency prohibits GHRP-2 in sport under Section S2 (peptide hormones/secretagogues). Research-grade material is sold for laboratory use only and is not approved for human consumption.

GHRP-2 FAQ

How is GHRP-2 different from GHRP-6 and Ipamorelin?

All three activate the same ghrelin/GH-secretagogue receptor (GHSR-1a). The differences are potency and selectivity. GHRP-2 is a more potent GH releaser than GHRP-6 and produces less appetite stimulation, but it still raises cortisol, prolactin, and ACTH modestly. Ipamorelin is the most selective of the group — GH-only, with essentially no cortisol or prolactin effect. GHRP-2 sits in the middle: stronger GH release than ipamorelin, cleaner than GHRP-6.

Is GHRP-2 approved for anything?

GHRP-2 (pralmorelin) is approved in Japan as a diagnostic agent for growth hormone deficiency — a single IV dose provokes a GH pulse that is measured to assess pituitary function. It is not FDA-approved for any therapeutic use in the United States and is sold elsewhere only as a research-grade peptide.

Does GHRP-2 raise cortisol?

Modestly, yes. Unlike ipamorelin (which is cortisol-sparing), GHRP-2 produces a small rise in cortisol, prolactin, and ACTH alongside GH. The effect is smaller than GHRP-6 but real — it is the main reason ipamorelin is often preferred for long-term use while GHRP-2 is favored where maximal GH release matters.

Will GHRP-2 make me hungry?

Yes, to a degree. GHRP-2 activates the ghrelin receptor, so appetite increases for a period after dosing — in a controlled study, healthy men ate about 36% more during a GHRP-2 infusion than with saline. The effect is real but generally less intense than GHRP-6. Bedtime dosing lets many users sleep through it.

Should I stack GHRP-2 with CJC-1295?

That is the standard pairing. GHRP-2 activates the ghrelin receptor while CJC-1295 activates the GHRH receptor; together they produce a larger GH pulse than either alone. Combining GHRP-2 with another ghrelin-receptor agonist (GHRP-6, hexarelin, ipamorelin, MK-677) is redundant.

How quickly does GHRP-2 work?

The GH pulse is immediate — peak GH typically occurs within about 15–60 minutes of a subcutaneous dose. Downstream effects (IGF-1 elevation, body-composition change) build over weeks of consistent dosing. The plasma half-life is short (roughly 30 minutes), so timing matters more than sustained blood levels.

Where can I buy GHRP-2?

GHRP-2 is sold by specialty research-peptide vendors. Prof. Peptide maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-45. https://pubmed.ncbi.nlm.nih.gov/6714155/
  2. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. https://pubmed.ncbi.nlm.nih.gov/10604470/
  3. Laferrère B, Abraham C, Russell CD, Bowers CY, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-4. https://pubmed.ncbi.nlm.nih.gov/15699539/
  4. Chihara K, Kodama H, Kaji H, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27. https://pubmed.ncbi.nlm.nih.gov/17609397/
  5. Mericq V, Cassorla F, Bowers CY, et al. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth-hormone-deficient children. J Clin Endocrinol Metab. 2003;88(4):1476-81. https://pubmed.ncbi.nlm.nih.gov/14513874/
  6. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28400207/
  7. Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring). 2006;14(6):1056-63. https://pubmed.ncbi.nlm.nih.gov/16861611/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

J Clin Endocrinol Metab / PubMed · 2005Abstract open
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men →

Laferrère B, Abraham C, Russell CD, Bowers CY, et al.

A controlled human study showing that GHRP-2, like the natural hormone ghrelin, stimulates appetite: seven lean healthy men ate roughly 36% more during a GHRP-2 infusion than during saline. It is the clearest human demonstration that GHRP-2's ghrelin-receptor activity produces a real, measurable increase in food intake — not just GH release.

Eur J Endocrinol / PubMed · 2007Abstract open
A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency →

Chihara K, Kodama H, Kaji H, et al.

A validation of GHRP-2 as a provocative diagnostic test for adult growth-hormone deficiency: a single 100 mcg intravenous dose produces a reproducible GH peak within about an hour, with a defined cut-off distinguishing GH-deficient patients. This is the basis for GHRP-2's (pralmorelin's) approved diagnostic use in Japan and underlines how potent and reliable its GH-releasing action is.

J Clin Endocrinol Metab / PubMed · 2003Abstract open
Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth-hormone-deficient children →

Mericq V, Cassorla F, Bowers CY, et al.

A longer-term study in GH-deficient children showing that repeated GHRP-2 administration increases appetite and body weight over time — consistent with sustained ghrelin-receptor activity. It illustrates both the GH-axis effect and the appetite effect persisting with ongoing dosing rather than fading immediately.

Sex Med Rev / PubMed · 2018Open Access
The Safety and Efficacy of Growth Hormone Secretagogues →

Sigalos JT, Pastuszak AW

A clinical review of the growth-hormone-secretagogue class (GHRP-2, GHRP-6, ipamorelin, and others). It summarizes the shared ghrelin-receptor mechanism, contrasts the compounds' selectivity, and is candid about the limited long-term human safety data — a useful evidence-honest anchor for GHRP-2's real research standing versus its marketing.

Prices and lab checks

Lowest price per mg

Lowest price per mg after Prof. Peptide's code, from the GHRP-2 price comparison.

  1. Fusion Peptide logo
    Fusion Peptide
    $2.01/mg
    10 mg · In stock · pulled October 24, 2026
  2. Real Peptides logo
    Real Peptides
    $2.40/mg
    10 mg · In stock · pulled October 24, 2026
  3. Alpha Peptides logo
    Alpha Peptides
    $2.58/mg
    5 mg · Out of stock · pulled October 24, 2026
  4. Solution Peptides logo
    Solution Peptides
    $2.66/mg
    5 mg · Out of stock · pulled October 24, 2026
  5. Healius Peptides logo
    Healius Peptides
    $2.70/mg
    10 mg · In stock · pulled October 24, 2026

Rows in the comparison's own order, up to five. Out-of-stock rows are included and each vial size is its own row; a vendor without a Prof. Peptide code shows its own price. Each date is that vendor's latest price pull.

Full comparison across 20 vendors

Median listed price per mg: $4.43 (July 26, 2026, 11 listings) → $3.90 (October 24, 2026, 27 listings); more vendors were added over the period.

Certificates checked at the lab

No GHRP-2 certificate is on Prof. Peptide’s record as matched at the issuing laboratory’s own lookup yet. A further 19 vendors carrying GHRP-2 in the price data name a testing laboratory, with no GHRP-2 certificate matched at the lab so far.

A match means the laboratory's own lookup returned the certificate as the vendor published it. It covers that certificate's lot, not the vendor's other lots or products.

Growth HormoneGHRPGHSR AgonistResearch-Grade

Related Peptides

GHRP-6HexarelinIpamorelinCJC-1295MK-677

Related Blends

GH Stack

We may earn commissions from peptide vendor affiliate links.

Have a question about GHRP-2? Send us an email